Does Aetna Pay for GLP-1 Medications? (2026)
Whether Aetna covers a GLP-1 depends on your specific plan; prior authorization is required, and members who are approved typically pay $25-$80 a month.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
If your question is only about Wegovy and Zepbound, read does Aetna cover Zepbound and Wegovy, which goes through Aetna's 2026 drug lists and prior-authorization criteria for both drugs.
Where Each Medication Stands[5]
| Medication | What Aetna does |
|---|---|
| Wegovy (semaglutide) | Start with the PBM, because it decides more here than the medical policy does. Aetna's pharmacy benefits run through CVS Caremark, and Wegovy is a preferred weight-loss drug on every 2026 Aetna drug list we read: the Standard Plan, Advanced Control and Standard Control lists all name it. The employer still chooses whether weight-management GLP-1s are covered at all. The clinical policy is bulletin 4774-C P08-2025 v5 (2026 edition) for Non-Medicare commercial plans. An adult has to be >=18 with BMI >=30, or BMI >=27 carrying one weight-related comorbidity, and must already have completed at least 6 months in a comprehensive weight-management program before drug therapy starts. Approval lands at 8 months. Reauthorization then runs 12 months at a time and needs at least 3 months at a stable maintenance dose, plus baseline body weight down by 5% or more, or a 5% loss held steady. Ages 12-17 enter at BMI in the 95th percentile or greater, on the same 6-month program requirement, with a 7-month first approval. 4774-C also carries a cardiovascular risk-reduction pathway for patients with established CVD who do NOT have type 2 diabetes, and a pathway for noncirrhotic MASH at fibrosis stage F2-F3 (the standard injection only, not Wegovy HD or the tablet). Quantity limits: 0.25-1 mg = 2 mL per 21 days; 1.7-2.4 mg = 3 mL per 21 days. |
| Ozempic (semaglutide) | Aetna now runs Ozempic, Mounjaro and the other diabetes GLP-1s through one bulletin, 2439-C P05-2025 v4 (2026 edition, latest date on the page March 18, 2026), and it is a type 2 diabetes policy throughout, not a weight-loss one. The diagnosis needs documentation: an A1C history of 6.5% or more, or a qualifying fasting, random or glucose-tolerance result. A new start, meaning a patient not already stable on a GLP-1 for 3 months or more, then needs one of several routes. Metformin has failed, been contraindicated or not been tolerated; combination therapy is needed with A1C at 7.5% or higher; or the patient has MASLD or MASH. For Ozempic injection specifically, established cardiovascular disease or chronic kidney disease also qualifies. A patient already on a stable maintenance dose goes through the continuation criteria instead. Approval runs 12 months. |
| Zepbound (tirzepatide) | Which Aetna drug list the plan uses now decides the answer, and the lists moved in 2026. Zepbound was added to the Aetna Standard Plan and High Value formularies on October 1, 2026, and the October 2026 Advanced Control Plan list names it among the preferred weight-loss options. The July 2026 Standard Control Plan list still excluded Zepbound and pointed members to Wegovy, so the July 2025 CVS Caremark move to Wegovy as the preferred GLP-1 still bites on some books. The clinical bulletin is 6947-C P04-2025, effective 07/01/2025 on Non-Medicare commercial plans and the latest Aetna Zepbound criteria we found. Adults qualify at BMI >=30, or BMI >=27 alongside a weight-related comorbid condition - hypertension, type 2 diabetes mellitus and dyslipidemia are the examples given - and must have spent at least 6 months in a comprehensive weight-management program before drug therapy. Renewal turns on documented >=5% loss from baseline body weight. A separate route covers moderate-to-severe OSA in adults with obesity at AHI >=15 events/hour. Exception bulletin 6981-A P04-2025, written for eight plan-formulary codes, names Wegovy as the primary alternative; Aetna has not said whether it still applies now that Zepbound is back on the main lists. On the Medicare side, Part D does NOT cover Zepbound for weight loss under the statutory exclusion, though the OSA indication may be payable. From 07/01/2026 the only formulation reaching Medicare members through the CMS Medicare GLP-1 Bridge is the KwikPen - not vials, not single-dose pens. Quantity limits hold across every strength: 1 package of 4 pens (2 mL) per 21 days, or 3 packages (6 mL) per 63 days. |
| Mounjaro (tirzepatide) | Mounjaro sits in the same combined diabetes bulletin as Ozempic, 2439-C P05-2025 v4 (2026 edition), so it is paid on type 2 diabetes and not for weight loss. The diagnosis has to be documented (an A1C history of 6.5% or more, or a qualifying glucose result). A new start then needs one of three routes: metformin inadequacy, intolerance or contraindication; combination therapy together with A1C >=7.5%; or a MASLD or MASH diagnosis. Patients already stable on a GLP-1 or Mounjaro for 3 months or more are handled under continuation. Approval runs 12 months, not the 36 months the older 5468-C bulletin allowed. |
| Foundayo (orforglipron) | Foundayo (orforglipron) now has a place on Aetna's lists. The October 1, 2026 Standard Plan update moved it from non-preferred to preferred, the High Value formulary added it the same day, and the October 2026 Advanced Control Plan list names it among the preferred weight-loss options. Aetna says it manages GLP-1 weight-loss coverage through prior authorization, and the employer still decides whether those drugs are covered at all, so ask the plan for its Foundayo criteria before filling. Medicare is the clearer half. Foundayo is inside the CMS Medicare GLP-1 Bridge from 07/01/2026 through 12/31/2027 at $50 a month; Aetna describes the Bridge as a CMS program outside its Medicare plans and says Aetna Medicare does not approve Bridge requests. This one moves. Re-verify against Aetna's primary source each quarter. |
| Saxenda (liraglutide) | The number to notice on Saxenda (liraglutide, for chronic weight management) is 4, not 5. Where Wegovy and Zepbound renew on a >=5% body-weight loss, bulletin 1227-C P08-2024_R (12/19/2024) renews Saxenda at >=4% of baseline, or a maintained 4% loss. Ages 12-17 renew on a different measure again: >=1% reduction in BMI from baseline. Getting in is otherwise familiar. BMI >=30 gets an adult in on its own. At BMI >=27 there has to be a weight-related comorbid condition alongside it, and the bulletin names hypertension, type 2 diabetes mellitus and dyslipidemia. On top of that sits at least 6 months in a comprehensive weight-management program before drug therapy, which Aetna defines as three things run together with continuing follow-up: behavioral modification, increased physical activity, and a reduced-calorie diet. For ages 12-17 the entry threshold is a BMI corresponding to >=30 kg/m^2 in adults by the international Cole Criteria cut-offs, on that same 6-month program. One exclusion to plan around: when the CMS Medicare GLP-1 Bridge takes effect on 07/01/2026, Saxenda is NOT in it. Dispensing caps: 1 package of five 3 mL pens (15 mL) per 25 days, or 3 packages (45 mL) per 75 days. |
| Copay when it is covered | $25-$80 / month |
What a GLP-1 costs a Aetna member
At Aetna's typical copay of $25-$80 a month, a covered year of a GLP-1 costs $300 to $960. That is $3,228 to $3,888 less than a year of Wegovy bought for cash from NovoCare ($4,188), and Zepbound's LillyDirect price of $299 to $449 a month is further above it still.
The cheapest compounded option, WellMedRx at $49/mo ($588 a year), lands inside the Aetna range, and 10 sellers charge no more than the $80 top of it, so for a member facing that copay a denial costs less than it sounds.
When Aetna covers the drug, a manufacturer savings card can bring a Wegovy or Zepbound fill down to $25, with each maker paying at most $100 a month.
Employers whose plans run through Aetna
Your employer decides much of this. Among the employers in our coverage checker, 4 use Aetna to run medical or pharmacy benefits: Amazon, JPMorgan Chase, US Postal Service (PSHB) and Brookfield. Amazon's Wegovy position, for example: Clinically eligible employees and adult dependents may receive GLP-1 medication through the 9amHealth weight management program (since Jan 1, 2026: BMI 35 or higher with two or more qualifying conditions, or BMI 27 or higher with heart disease). 9amHealth does not name which GLP-1 brands are covered; copays/cost-shares may apply. Verify the specific drug with A to Z Benefits or MyHR.
After a Denial from Aetna
A Aetna denial leaves two routes: an appeal, and paying cash. With a prescription, a brand-name GLP-1 is generally an eligible HSA or FSA medical expense[3]. Compounded semaglutide and tirzepatide from licensed 503A pharmacies[4] cost far less than the brand; the cheapest sellers are listed below.
If a large employer self-funds your Aetna plan, ERISA rather than state insurance law applies and the employer decides whether anti-obesity drugs are covered[2]; the Summary Plan Description says which.
Every Aetna GLP-1 bulletin is reproduced word for word in our guide: the CVS Caremark formulary swap of July 2025 that made Wegovy preferred, which drives most 2026 denials; the metformin-first step rule on Mounjaro and Ozempic; the Zepbound 6981-A exception, carried on plan codes ACCF, ACF and ACFC, plus SCCF, SF, SFC, VF and VFC; the Wegovy reauth window of 7 months; the Saxenda continuation threshold set at 4% (NOT 5%); the CMS Medicare GLP-1 Bridge, which starts 07/01/2026; and how Foundayo is handled. Read it in the Aetna GLP-1 Prior Authorization Guide.
Where to go if Aetna says no
Sellers that say they work with Aetna
The 8 cheapest cash-pay compounded GLP-1s
| # | Seller | Monthly price | Score | Visit |
|---|---|---|---|---|
| 1 | WellMedRx Compounded semaglutide | $49/mo | 6.3 | Visit |
| 2 | Collective Compounded semaglutide | $59/mo | 9.1 | Visit |
| 3 | RenewlyRX Compounded semaglutide | $68/mo | 6.6 | Review |
| 4 | Lean Meds Compounded semaglutide | $79/mo | 9.4 | Review |
| 5 | Tryozi Compounded semaglutide | $79/mo | 9.4 | Review |
| 6 | Embody Compounded semaglutide | $79/mo | 9.3 | Visit |
| 7 | NextMeds Compounded semaglutide | $79/mo | 9.3 | Review |
| 8 | CoreAge Rx Compounded semaglutide | $79/mo | 9.0 | Visit |
Every seller and price, side by side: compare all sellers.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Prior authorization (PA) · Insurance and regulatory
- Step therapy · Insurance and regulatory
- PBM (Pharmacy Benefit Manager) · insurance
- Formulary tier · Insurance and regulatory
- Copay accumulator · insurance
- Manufacturer coupon · insurance
- Quantity limit · insurance
Sources & methodology — as of November 2026
- 1.KFF — Employer Health Benefits Annual Survey— Kaiser Family Foundation.
- 2.U.S. Department of Labor — ERISA and Employer Health Plans— U.S. Department of Labor, Employee Benefits Security Administration.
- 3.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
- 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 5.GLP Watchdog insurer coverage index (manually curated formulary data)— GLP Watchdog.